About Intellipharmaceutics International
Intellipharmaceutics International was a publicly listed company based in Toronto (Canada) founded in 1998. It specializes in developing generic controlled-release oral solid dosage drugs for pharmaceutical markets. It operates on a B2B model. The company is recorded as dissolved. Its focus areas include Pharmaceuticals, Drug Development and Generic Medications. Its legal entity is Intellipharmaceutics International Inc.
Company details
Intellipharmaceutics International specializes in developing generic controlled-release oral solid dosage drugs for pharmaceutical markets through providing healthcare solutions, producing pharmaceutical products, drug development, and generic medications. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field.
- Headquarters Toronto, Canada
- Stage Public
- SectorsHealthcare
- Website intellipharmaceutics.com
- Social Facebook
- Legal Name Intellipharmaceutics Intl Inc
- Annual Revenue$63.41 K (USD)as on Nov 30, 2022
- Net Profit-$2.79 M (USD)44.7as on Nov 30, 2022
- EBITDA-$2.54 M (USD)33.85as on Nov 30, 2022
- Latest Funding Round$250K (USD), Post-IPO
Nov 2019
Funding Insights of Intellipharmaceutics International
- Total Rounds 6
- Last Round Post-IPO — $250,000
- First Round $12M
(Feb 2011)
- Investors Count 1
All 6 funding rounds of Intellipharmaceutics International with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2019 | $250,000 | Post-IPO | – | – | |
| Mar 2018 | $3.3M | Post-IPO | – | – | – |
| Mar 2018 | $1.8M | Post-IPO | – | – | – |
| Oct 2017 | $4M | Post-IPO | – | – | – |
| Mar 2013 | $3.1M | Post-IPO | – | – | – |
| Feb 2011 | $12M | Post-IPO | – | – | – |
1 investors in total: 0 institutional and 1 angel.
Investors in Intellipharmaceutics International
Intellipharmaceutics International has secured backing from 1 investor, including angel investors. Prominent investors backing the company include Amina Odidi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
AO Amina Odidi | unknown_bab4e478aecb43b49 |
Investor details for Intellipharmaceutics International
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Intellipharmaceutics International
8 people are tracked at Intellipharmaceutics International (3 in leadership, 5 in team).
| Name | Role | Group |
|---|---|---|
Isa Odidi | Chairman & CEO | Leadership |
Amina Odidi | President, COO, Co-Chief Scientific Officer (CSO) | Leadership |
Patrick N. Yat | Vice President, Chemistry & Analytical Services | Leadership |
Zobia Sharif | Regulatory Affairs/quality Assurance Specialist | Team |
Jamie Chen | Scientist | Team |
Vajesh Bhagat | Processing Technologist | Team |
Nauman Sharif | Analytical Chemist | Team |
Giuwa Amadasun | Validation Specialist | Team |
Complete people profiles for Intellipharmaceutics International
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Intellipharmaceutics International
Intellipharmaceutics International is a publicly listed company on the OTC with ticker symbol IPCIQ in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Jan 2003
- Listed onNASDAQ: IPCIF
- Listed entityINTELLIPHARMACEUTICS INTL INC
- Exchange sectorHealth technology
- ISINCA4581733090
- Share price$0.00 · 2026-10-06
- Volume (last session)300
Financials of Intellipharmaceutics International
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2022 | $63,410 | -$2.8M | -$2.5M |
| 2021 | -$5.0M | -$3.8M | |
| 2020 | $1.4M | -$3.5M | -$4.4M |
Detailed financial statements for Intellipharmaceutics International
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Intellipharmaceutics International
4 dated milestones of Intellipharmaceutics International across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Intellipharmaceutics International is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $12.0M.
- Funding Latest funding round, Post-IPO, of $250K.
Web traffic of Intellipharmaceutics International
Websites that share an audience with Intellipharmaceutics International (intellipharmaceutics.com).
Websites whose visitors overlap most with Intellipharmaceutics International. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| skyepharma.com | 95% | View details | |||
| capsugel.com | 79% | 37.5K | #823,274 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Intellipharmaceutics International
Complete news archive for Intellipharmaceutics International
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intellipharmaceutics International
Intellipharmaceutics International was founded in 1998 and raised its 1st funding round 13 years after it was founded.
Intellipharmaceutics International is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Annual revenue of Intellipharmaceutics International is $63.41K as on Nov 30, 2022.
Intellipharmaceutics International specializes in developing generic controlled-release oral solid dosage drugs for pharmaceutical markets through providing healthcare solutions, producing pharmaceutical products, drug development, and generic medications. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field.
Yes, Intellipharmaceutics International is publicly traded on OTC under the ticker symbol IPCIQ.
Intellipharmaceutics International has 1 investor. Key investors include Amina Odidi.
Intellipharmaceutics International operates through Intellipharmaceutics International Inc..